- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 4.30 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.2: 5 residues within 4Å:- Chain A: V.104, T.105, N.118, S.120, Y.135
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.23: 5 residues within 4Å:- Chain G: V.104, T.105, N.118, S.120, Y.135
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.44: 5 residues within 4Å:- Chain M: V.104, T.105, N.118, S.120, Y.135
No protein-ligand interaction detected (PLIP)- 21 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.3: 6 residues within 4Å:- Chain A: T.98, Q.100, S.120, N.122, K.131, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG.4: 4 residues within 4Å:- Chain A: V.144, R.162, N.167
- Chain M: R.278
No protein-ligand interaction detected (PLIP)NAG-NAG.5: 4 residues within 4Å:- Chain A: N.204, T.206, S.244, I.247
No protein-ligand interaction detected (PLIP)NAG-NAG.7: 5 residues within 4Å:- Chain A: N.265, N.301, S.303, S.381, V.414
No protein-ligand interaction detected (PLIP)NAG-NAG.8: 2 residues within 4Å:- Chain A: N.271, I.292
No protein-ligand interaction detected (PLIP)NAG-NAG.10: 6 residues within 4Å:- Chain A: N.332, S.333, S.357
- Ligands: NAG-NAG.11, NAG-NAG.11, NAG-NAG-BMA.12
No protein-ligand interaction detected (PLIP)NAG-NAG.11: 4 residues within 4Å:- Chain A: N.355, S.357
- Ligands: NAG-NAG.10, NAG-NAG.10
No protein-ligand interaction detected (PLIP)NAG-NAG.24: 6 residues within 4Å:- Chain G: T.98, Q.100, S.120, N.122, K.131, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG.25: 4 residues within 4Å:- Chain A: R.278
- Chain G: V.144, R.162, N.167
No protein-ligand interaction detected (PLIP)NAG-NAG.26: 4 residues within 4Å:- Chain G: N.204, T.206, S.244, I.247
No protein-ligand interaction detected (PLIP)NAG-NAG.28: 5 residues within 4Å:- Chain G: N.265, N.301, S.303, S.381, V.414
No protein-ligand interaction detected (PLIP)NAG-NAG.29: 2 residues within 4Å:- Chain G: N.271, I.292
No protein-ligand interaction detected (PLIP)NAG-NAG.31: 6 residues within 4Å:- Chain G: N.332, S.333, S.357
- Ligands: NAG-NAG.32, NAG-NAG.32, NAG-NAG-BMA.33
No protein-ligand interaction detected (PLIP)NAG-NAG.32: 4 residues within 4Å:- Chain G: N.355, S.357
- Ligands: NAG-NAG.31, NAG-NAG.31
No protein-ligand interaction detected (PLIP)NAG-NAG.45: 6 residues within 4Å:- Chain M: T.98, Q.100, S.120, N.122, K.131, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG.46: 4 residues within 4Å:- Chain G: R.278
- Chain M: V.144, R.162, N.167
No protein-ligand interaction detected (PLIP)NAG-NAG.47: 4 residues within 4Å:- Chain M: N.204, T.206, S.244, I.247
No protein-ligand interaction detected (PLIP)NAG-NAG.49: 5 residues within 4Å:- Chain M: N.265, N.301, S.303, S.381, V.414
No protein-ligand interaction detected (PLIP)NAG-NAG.50: 2 residues within 4Å:- Chain M: N.271, I.292
No protein-ligand interaction detected (PLIP)NAG-NAG.52: 6 residues within 4Å:- Chain M: N.332, S.333, S.357
- Ligands: NAG-NAG.53, NAG-NAG.53, NAG-NAG-BMA.54
No protein-ligand interaction detected (PLIP)NAG-NAG.53: 4 residues within 4Å:- Chain M: N.355, S.357
- Ligands: NAG-NAG.52, NAG-NAG.52
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.6: 12 residues within 4Å:- Chain A: K.35, S.179, E.181, P.182, N.232, N.346, C.347, G.348, Q.408, V.414, S.415
- Ligands: NAG-NAG-BMA.13
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:G.348
NAG-NAG-BMA-MAN-MAN-MAN.27: 12 residues within 4Å:- Chain G: K.35, S.179, E.181, P.182, N.232, N.346, C.347, G.348, Q.408, V.414, S.415
- Ligands: NAG-NAG-BMA.34
1 PLIP interactions:1 interactions with chain G- Hydrogen bonds: G:G.348
NAG-NAG-BMA-MAN-MAN-MAN.48: 12 residues within 4Å:- Chain M: K.35, S.179, E.181, P.182, N.232, N.346, C.347, G.348, Q.408, V.414, S.415
- Ligands: NAG-NAG-BMA.55
1 PLIP interactions:1 interactions with chain M- Hydrogen bonds: M:G.348
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.9: 17 residues within 4Å:- Chain A: T.267, R.296, H.299, N.301, D.380, T.383
- Chain B: S.24, N.44, N.45, N.46, P.60, G.61, S.62
- Chain F: R.103, I.104, G.106, V.107
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:R.296, A:R.296
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.30: 17 residues within 4Å:- Chain G: T.267, R.296, H.299, N.301, D.380, T.383
- Chain H: S.24, N.44, N.45, N.46, P.60, G.61, S.62
- Chain L: R.103, I.104, G.106, V.107
2 PLIP interactions:2 interactions with chain G- Hydrogen bonds: G:R.296, G:R.296
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.51: 17 residues within 4Å:- Chain M: T.267, R.296, H.299, N.301, D.380, T.383
- Chain N: S.24, N.44, N.45, N.46, P.60, G.61, S.62
- Chain R: R.103, I.104, G.106, V.107
2 PLIP interactions:2 interactions with chain M- Hydrogen bonds: M:R.296, M:R.296
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.12: 2 residues within 4Å:- Chain A: N.361
- Ligands: NAG-NAG.10
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.13: 4 residues within 4Å:- Chain A: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.6
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.33: 2 residues within 4Å:- Chain G: N.361
- Ligands: NAG-NAG.31
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.34: 4 residues within 4Å:- Chain G: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.27
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.54: 2 residues within 4Å:- Chain M: N.361
- Ligands: NAG-NAG.52
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.55: 4 residues within 4Å:- Chain M: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.48
No protein-ligand interaction detected (PLIP)- 24 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.14: 4 residues within 4Å:- Chain A: T.102, N.103, D.110, R.113
Ligand excluded by PLIPNAG.15: 8 residues within 4Å:- Chain A: N.107, I.108
- Chain B: W.88, D.89, R.92, T.94
- Chain F: F.114, T.115
Ligand excluded by PLIPNAG.16: 2 residues within 4Å:- Chain A: N.246, T.248
Ligand excluded by PLIPNAG.17: 1 residues within 4Å:- Chain A: N.324
Ligand excluded by PLIPNAG.18: 1 residues within 4Å:- Chain A: N.308
Ligand excluded by PLIPNAG.19: 2 residues within 4Å:- Chain D: N.100, S.102
Ligand excluded by PLIPNAG.20: 2 residues within 4Å:- Chain D: E.123, N.126
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain F: S.7, T.21, N.23
Ligand excluded by PLIPNAG.35: 4 residues within 4Å:- Chain G: T.102, N.103, D.110, R.113
Ligand excluded by PLIPNAG.36: 8 residues within 4Å:- Chain G: N.107, I.108
- Chain H: W.88, D.89, R.92, T.94
- Chain L: F.114, T.115
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain G: N.246, T.248
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain G: N.324
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain G: N.308
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain J: N.100, S.102
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain J: E.123, N.126
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain L: S.7, T.21, N.23
Ligand excluded by PLIPNAG.56: 4 residues within 4Å:- Chain M: T.102, N.103, D.110, R.113
Ligand excluded by PLIPNAG.57: 8 residues within 4Å:- Chain M: N.107, I.108
- Chain N: W.88, D.89, R.92, T.94
- Chain R: F.114, T.115
Ligand excluded by PLIPNAG.58: 2 residues within 4Å:- Chain M: N.246, T.248
Ligand excluded by PLIPNAG.59: 1 residues within 4Å:- Chain M: N.324
Ligand excluded by PLIPNAG.60: 1 residues within 4Å:- Chain M: N.308
Ligand excluded by PLIPNAG.61: 2 residues within 4Å:- Chain P: N.100, S.102
Ligand excluded by PLIPNAG.62: 2 residues within 4Å:- Chain P: E.123, N.126
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain R: S.7, T.21, N.23
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Kong, R. et al., Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science (2016)
- Release Date
- 2016-05-25
- Peptides
- BG505 SOSIP.664 gp120: AGM
PGT122 Fab light chain: BHN
VRC34.01 Fab heavy chain: CIO
BG505 SOSIP.664 gp41: DJP
VRC34.01 Fab light chain: EKQ
PGT122 Fab heavy chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
CG
CM
CB
LH
LN
LC
GI
GO
GD
DJ
DP
DE
HK
HQ
HF
KL
KR
K
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 4.30 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 21 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 24 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Kong, R. et al., Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science (2016)
- Release Date
- 2016-05-25
- Peptides
- BG505 SOSIP.664 gp120: AGM
PGT122 Fab light chain: BHN
VRC34.01 Fab heavy chain: CIO
BG505 SOSIP.664 gp41: DJP
VRC34.01 Fab light chain: EKQ
PGT122 Fab heavy chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
CG
CM
CB
LH
LN
LC
GI
GO
GD
DJ
DP
DE
HK
HQ
HF
KL
KR
K